Eli Lilly and Company
LLY
$1347.11
-0.30%
Eli Lilly and Company is a global pharmaceutical manufacturer whose portfolio spans cardiometabolic health (Mounjaro, Zepbound, Trulicity, Jardiance, Humalog/Humulin), oncology (Verzenio, Jaypirca), immunology (Taltz, Olumiant), and neuroscience, with cardiometabolic products now overwhelmingly the growth engine at roughly $19.8B of the latest quarterly segment revenue. Lilly has evolved from a diversified legacy drugmaker into the undisputed platform leader of the incretin/obesity era, leveraging first-mover advantage in GLP-1/GIP dual agonists and the deepest metabolic pipeline in the industry to command pricing power and manufacturing scale that smaller obesity challengers cannot yet match. The current investor narrative is dominated by the post-Q3 earnings rally after management raised 2026 sales guidance to as much as $92 billion, with bulls pointing to Zepbound/Mounjaro demand durability, oral GLP-1 optionality, and capacity expansion, while bears debate premium valuation, looming competition from Novo Nordisk's oral Wegovy and CagriSema, and pipeline challengers like Viking Therapeutics. Sentiment has clearly swung positive into November, with the stock pressing all-time highs and sell-side firms reiterating bullish ratings en masse following the print.…
LLY
Eli Lilly and Company
$1347.11
Related headlines
Investment Opinion: Should I buy LLY Today?
Rating: Hold (with a bias to accumulate on pullbacks). The core thesis is that Eli Lilly is the undisputed platform leader of the incretin/obesity era — 38.61% YoY revenue growth, 83.04% gross margin, and a PEG of 0.48 — but at $1,443.50 the stock trades at 98.9% of its 52-week range with only +1.4% implied upside to the $1,463.40 consensus target, meaning the post-Q3 re-rating has already captured most of the near-term value. The 25 Buy / 4 Hold / 2 Sell split (recommendation mean 1.65) confirms strong conviction, but the balance of evidence favors patience over chasing at all-time highs.
Supporting evidence is genuinely elite: forward PE of 28.50x against trailing 46.58x implies 39% EPS growth is already discounted, yet the PEG of 0.48 says growth more than pays for the multiple; revenue stepped up sequentially from $19.799B (Q1) to $22.974B (Q2) to $24.397B (Q3); trailing gross margin of 83.04% and net margin of 31.67% are two to three times mature pharma peers; TTM free cash flow of $19.661B comfortably funds $4.247B of quarterly R&D and the 26.09% payout ratio; and the stock has outperformed SPY by 28.85 points over one year with a beta of just 0.389. Against the 3–6x sales range typical of large-cap pharma, however, LLY's 14.81x PS and 15.39x EV/Sales are a growth multiple that assumes the 30%+ trajectory persists.
The biggest risks that could invalidate the thesis are (1) incretin concentration — Cardiometabolic at $19.764B of segment revenue versus Oncology at $2.60B means a single franchise carries the entire growth story; (2) competitive share loss to Novo's oral Wegovy and CagriSema (25% weight loss in Phase 3) plus Viking's funded VK2735 Phase 3; and (3) earnings noise from one-off items, evidenced by operating margin swinging from 54.22% in Q2 to 35.28% in Q3 on a $4.484B other-expense line. This Hold would upgrade to Buy on a pullback toward the $1,350–1,365 consolidation support (roughly -5% to -6%, restoring ~5–6% upside to consensus) or on evidence of 2027 estimate revisions above the current $73.21 EPS; it would downgrade to Sell if Zepbound/Mounjaro growth decelerates below 20% or Novo's oral Wegovy forces visible pricing concessions. Verdict: fairly valued at consensus, not overvalued relative to its own de-rated history (46.58x trailing PE sits in the middle-to-lower portion of a 27.8x–205x band), but priced for continued execution with no margin of safety at current levels.
Sign up to view all
LLY 12-Month Price Forecast
The forward view is balanced: Lilly's fundamentals are exceptional and still accelerating, but the price already reflects them after a 41.12% one-year gain that beat SPY by 28.85 points, leaving only +1.4% to the consensus target. The base case (55%) assumes high-20s to low-30s revenue growth and 2027 EPS near $73.21, holding the stock in a $1,400–1,500 range around the $1,463.40 average target. The bull case (25%) requires oral GLP-1 expansion and estimate revisions toward the $78.11 high EPS to justify the $1,700 high target, while the bear case (20%) hinges on Novo's oral Wegovy and CagriSema eroding share and compressing the multiple toward 20x, a path to the $940 low target. I would upgrade to bullish on a pullback into the $1,350–1,365 support that restores 5–6% upside to consensus, or on 2027 EPS revisions above $73.21; I would downgrade to bearish if incretin growth decelerates below 20% or gross margin slips below 80% on competitive pricing.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Eli Lilly and Company's 12-month outlook, with a consensus price target around $1470.06 and implied upside of +9.1% versus the current price.
Average Target
$1470.06
31 analysts
Implied Upside
+9.1%
vs. current price
Analyst Count
31
covering this stock
Price Range
$940 - $1700
Analyst target range
Coverage is deep and overwhelmingly bullish: 29 analysts with 25 Buy, 4 Hold, and 2 Sell ratings, a consensus recommendation of "buy" and a recommendation mean of 1.65 (where 1.0 is a strong buy). The average target price of $1,463.40 implies just +1.4% upside from the current $1,443.50 — essentially fair value at consensus — which suggests the stock has already caught up to the Street's models after the post-Q3 rally, and further upside now requires estimate revisions rather than multiple re-rating. Consensus 2027 EPS of $73.21 and revenue of ~$141.4B underpin that target, so the setup is "hold with upside optionality" rather than a fresh buy at current levels.
The target range is wide — $940 low to $1,700 high, a 81% spread — signaling genuine disagreement about the durability of the obesity franchise and competitive intensity. The $1,700 high target implies continued share gains, oral GLP-1 expansion, and multiple expansion toward 30x+ forward earnings, while the $940 low bakes in margin compression from Novo Nordisk's oral Wegovy and CagriSema competition plus pipeline disappointments. Institutional ratings show a clear pattern of reiteration rather than downgrades — Jefferies (Buy), Cantor Fitzgerald (Overweight), JPMorgan (Overweight), Morgan Stanley (Overweight), Wells Fargo (Overweight), RBC (Outperform), Truist (Buy), Argus (Buy), and Citigroup (Buy) all reaffirmed in late October/early November — indicating strong conviction but also that upgrades are largely priced in; the risk/reward is now more balanced, with the stock trading essentially at consensus fair value.
Bulls vs Bears: LLY Investment Factors
The bull case currently has stronger evidence: 38.61% revenue growth, 83%+ gross margins, a PEG of 0.48, and 41% one-year outperformance of SPY are hard, current facts, whereas the bear case rests largely on forward-looking competitive risk and a valuation premium that has actually compressed on a forward basis. The bear side is not weak, however — at $1,443.50 the stock trades at 98.9% of its 52-week range with only +1.4% implied upside to the $1,463.40 consensus target, so the easy money from the post-Q3 re-rating has been made. The single most important tension is whether the incretin franchise can sustain 30%+ growth against Novo's oral Wegovy and CagriSema and Viking's VK2735; if Zepbound/Mounjaro share holds through 2027, the 28.50x forward PE is cheap for the growth, but any deceleration would expose the 14.81x PS premium. With beta of 0.389 and a shallow -23.31% max drawdown, downside is likely to be gradual rather than violent, but the risk/reward at current levels is balanced rather than compelling.
Bullish
- Revenue accelerating at 38.6% YoY: Q3 2026 revenue of $24.397B grew 38.61% versus $17.601B in Q3 2025, and the sequential cadence ($19.799B → $22.974B → $24.397B) shows consistent step-ups rather than a one-off spike. Management's raised 2026 sales guidance of up to $92B implies the Q4 run-rate holds or improves.
- Elite margins fund self-reliant growth: Trailing gross margin of 83.04% and net margin of 31.67% are two to three times mature pharma peers, with Q3 gross margin at 83.88% and operating margin of 35.28%. R&D of $4.247B (17.4% of revenue) is comfortably funded from the P&L, and ROE of 77.78% shows highly efficient capital deployment.
- Valuation de-rated despite price rally: At 46.58x trailing but 28.50x forward earnings, the multiple compresses 39% on expected EPS growth, and the PEG of 0.48 signals growth more than pays for the multiple. The stock sits in the middle-to-lower portion of its own multi-year PE band (27.8x to 205x), meaning the rally has been earnings-driven, not pure multiple expansion.
- Massive relative strength, low beta: LLY is up 41.12% over one year and 33.61% YTD, outperforming SPY by 28.85 and 22.99 percentage points respectively, with +21.68 (1M) and +25.14 (3M) relative strength as SPY fell. Beta of just 0.389 means this momentum comes with historically below-market volatility, allowing larger notional position sizing.
Bearish
- Consensus upside nearly exhausted: The $1,463.40 average target implies only +1.4% upside from $1,443.50, essentially fair value at consensus. Further gains now require estimate revisions rather than multiple re-rating, and the stock at 98.9% of its 52-week range leaves little margin of safety.
- Extreme premium to pharma peers: PS of 14.81x and EV/Sales of 15.39x are far above the 3–6x range typical of large-cap pharma, while P/B of 36.37x and EV/EBITDA of 31.57x reflect a growth multiple. This premium leaves little room for execution error, and the 0.56% dividend yield offers no income cushion.
- Incretin concentration is the whole thesis: Cardiometabolic Health generated $19.764B of segment revenue versus Oncology at $2.60B, Immunology at $1.435B, and Neuroscience at $0.444B. The investment case is effectively a single-franchise bet, so any GLP-1/GIP demand or pricing shock hits the entire growth story.
- Margin volatility and one-off drags: Q3 net margin fell to 26.44% from Q2's 30.88% on a $4.484B other-expense line and higher tax, and operating margin swung from 54.22% in Q2 to 35.28% in Q3. This quarter-to-quarter noise shows earnings are sensitive to non-operating items even as revenue compounds.
LLY Technical Analysis
LLY is in a powerful, sustained uptrend: the stock is up 41.12% over the past year and 33.61% YTD, and at $1,443.50 it sits at roughly 98.9% of its 52-week range (low $850.51, high $1,460.00), just 1.1% below the high. This positioning signals strong momentum leadership rather than a value setup — the stock is knocking on the door of all-time-high territory, and the shallow max drawdown of -23.31% over the period confirms dip-buyers have repeatedly stepped in. Relative strength is exceptional, with LLY outperforming SPY by 28.85 percentage points over one year and 22.99 points YTD.
Short-term momentum is accelerating rather than fading: the stock gained 19.42% in the last month and 22.31% over three months, both well ahead of the 41.12% one-year pace on an annualized basis, and the 6-month change of 43.64% shows the move is broadening. Critically, this strength is idiosyncratic — SPY fell 2.26% over the past month and 2.83% over three months, producing relative strength readings of +21.68 (1M) and +25.14 (3M), which points to a post-earnings re-rating rather than beta-driven drift. The most recent session added another 1.14% on a close of $1,443.50, confirming buyers remain in control near the highs.
Key resistance sits at the $1,460.00 52-week high; a clean breakout would likely trigger momentum-chasing flows and open blue-sky territory, while failure there could produce a short-term double-top pullback. Support is layered at the $1,350–1,365 area (early-November consolidation) and, more structurally, at the $850.51 52-week low — a level that underscores how extended the trend is. Notably, beta of just 0.389 means LLY has historically been far less volatile than the market, so despite the steep absolute price, position sizing can tolerate a larger notional allocation than a high-beta name; the 2.84 short ratio indicates short interest is modest and not a major squeeze or overhang factor.
Beta
0.39
0.39x market volatility
Max Drawdown
-23.3%
Largest decline past year
52-Week Range
$851-$1475
Price range past year
Annual Return
+29.1%
Cumulative gain past year
| Period | LLY Return | S&P 500 |
|---|---|---|
| 1m | +6.0% | -9.7% |
| 3m | +7.3% | -9.9% |
| 6m | +26.5% | -7.5% |
| 1y | +29.1% | +4.7% |
| ytd | +24.7% | +1.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
LLY Fundamental Analysis
Revenue growth is not just strong but accelerating: Q3 2026 revenue of $24.397B grew 38.61% year-over-year versus $17.601B in Q3 2025, and the sequential cadence ($19.799B in Q1, $22.974B in Q2, $24.397B in Q3) shows consistent step-ups each quarter. Cardiometabolic Health dominates at $19.764B of segment revenue, dwarfing Oncology at $2.60B, Immunology at $1.435B, and Neuroscience at $0.444B — meaning the incretin franchise is effectively the whole investment case, a concentration risk but also the source of the 38%+ growth. Management's raised 2026 sales forecast of up to $92B implies the Q4 run-rate holds or improves, and consensus revenue estimates of ~$141.4B (likely a forward-year figure) reinforce that the growth runway is being priced as durable.
Profitability is elite: Q3 net income was $6.451B on a 26.44% net margin (down from Q2's 30.88% due to a $4.484B other-expense line and higher tax), while gross margin held at 83.88% and operating margin reached 35.28% in Q3 versus 54.22% in Q2. The Q2 operating margin of 54.22% versus Q1's 49.39% and Q3's 35.28% shows some quarter-to-quarter noise from one-off items, but the trailing gross margin of 83.04% and net margin of 31.67% are exceptional for large-cap pharma and reflect pricing power plus manufacturing leverage. R&D spend of $4.247B in Q3 (17.4% of revenue) is being funded comfortably from the P&L, and the 77.78% ROE underscores how efficiently equity is being deployed.
Cash generation is robust but capital-hungry: TTM free cash flow is $19.661B, with Q3 FCF of $8.219B on operating cash flow of $11.397B against $3.178B of capex, and Q2 FCF of $7.757B. The balance sheet carries debt-to-equity of 1.60 and a current ratio of 1.58, with Q2 seeing $11.577B of debt repayment alongside $8.747B of acquisitions — evidence the company is actively deploying cash into capacity and bolt-ons. Liquidity is adequate but not lavish (Q3 cash of $4.885B after $5.284B of debt repayment and $1.541B of dividends), and the 26.09% payout ratio leaves ample room to keep funding growth internally without external financing dependence.
Quarterly Revenue
$24.4B
2026-09
Revenue YoY Growth
+38.6%
YoY Comparison
Gross Margin
83.9%
Latest Quarter
Free Cash Flow
$19.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is LLY Overvalued?
Because net income is solidly positive ($6.451B in Q3 alone), the PE ratio is the appropriate primary metric: LLY trades at 46.58x trailing earnings but only 28.50x forward earnings, a 39% compression that implies the market expects substantial EPS growth — consistent with consensus 2027 EPS estimates of ~$73.21 versus the current run-rate. The PEG ratio of 0.48 is strikingly low for a 46x PE stock, suggesting growth is more than paying for the multiple, though the trailing PE of 46.58x versus a forward PE of 28.50x also flags that near-term earnings are still ramping against a high base.
On peer comparison, LLY's 14.81x PS and 15.39x EV/Sales are far above typical large-cap pharma (most peers trade in the 3–6x sales range), and its 36.37x P/B and 31.57x EV/EBITDA reflect a premium growth multiple rather than a value multiple. The premium is defensible given 38.61% revenue growth, 83.04% gross margin, and 31.67% net margin — metrics that are two to three times what mature pharma peers deliver — but it leaves little room for execution error, and the 0.56% dividend yield offers no income cushion. In short, investors are paying a growth-stock multiple for a company that is currently growing like a growth stock.
Historically, LLY's own valuation band has been wide: PE ranged from roughly 27.8x (Q1 2026) to 205x (Q3 2024, when earnings were depressed), and PS ranged from ~38.9x (Q3 2025) to ~78.1x (Q1 2024). At 46.58x trailing PE and 14.81x PS, the stock sits in the middle-to-lower portion of its multi-year band — meaning the current multiple is not stretched relative to its own history, and the earnings growth has actually de-rated the stock on a PE basis even as the price has risen. That is a constructive signal: the rally has been earnings-driven rather than pure multiple expansion.
PE
46.6x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 28x~76x
vs. Industry Avg
18.6x
Industry PE ~18.6x*
EV/EBITDA
31.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on concentration and cash deployment. Cardiometabolic Health at $19.764B of segment revenue dwarfs Oncology ($2.60B), Immunology ($1.435B), and Neuroscience ($0.444B), so a single franchise carries the growth thesis, and Q3 net margin already slipped to 26.44% from Q2's 30.88% on a $4.484B other-expense line. Debt-to-equity of 1.60 and a current ratio of 1.58 are manageable but not fortress-like, and Q3 cash fell to $4.885B after $5.284B of debt repayment and $1.541B of dividends, while $8.747B of Q2 acquisitions and $3.178B of quarterly capex show the company is consuming capital to defend its manufacturing and pipeline lead. The 26.09% payout ratio and $19.661B TTM free cash flow provide cushion, but earnings volatility from one-off items (operating margin swinging from 54.22% in Q2 to 35.28% in Q3) means headline profitability can disappoint even in strong revenue quarters.
Market and competitive risks are dominated by valuation compression and the obesity arms race. At 14.81x PS and 15.39x EV/Sales versus the 3–6x typical of large-cap pharma, LLY carries a growth multiple that assumes continued 30%+ growth; a deceleration toward 20% would likely compress the multiple toward 20x forward earnings. Recent news highlights the threat: Novo Nordisk's oral Wegovy pill launch is succeeding under a high-volume/low-price strategy, CagriSema posted 25% weight loss in Phase 3, and Viking Therapeutics raised $575M to fund VK2735 Phase 3 into 2028. Beta of just 0.389 limits broad-market correlation, but that low beta also means the stock's risk is idiosyncratic — sector rotation out of premium healthcare growth names or a single competitive headline can move LLY independently of SPY, which fell 2.26% over the past month while LLY gained 19.42%.
The worst-case scenario is a competitive share-loss shock coinciding with multiple compression: Novo's oral Wegovy and CagriSema take GLP-1 share, Zepbound/Mounjaro growth decelerates below 20%, and the market re-rates LLY from 28.50x toward 20x forward earnings. The $940 analyst low target implies roughly -35% from the current $1,443.50, and the 52-week low of $850.51 implies about -41%, consistent with the -23.31% max drawdown already experienced over the past year. A realistic adverse path is a pullback to the $1,350–1,365 consolidation support (-5% to -6%) on a single disappointing print, extending to the $940–$1,000 zone (-31% to -35%) if competitive data forces estimate cuts across 2027.
FAQ
The most severe risk is competitive erosion of the incretin franchise: Cardiometabolic Health at $19.764B of segment revenue versus Oncology at $2.60B means a single franchise carries the thesis, and Novo's oral Wegovy plus CagriSema's 25% Phase 3 weight loss and Viking's funded VK2735 are live threats. Second is valuation compression — 14.81x PS and 15.39x EV/Sales assume 30%+ growth, so a deceleration toward 20% could compress the multiple toward 20x forward earnings and the $940 low target (-35%). Third is earnings volatility from one-off items, evidenced by operating margin swinging from 54.22% in Q2 to 35.28% in Q3 on a $4.484B other-expense line, which can produce headline misses even in strong revenue quarters. Fourth is capital intensity and balance-sheet leverage — debt-to-equity of 1.60, $3.178B of quarterly capex, and $8.747B of Q2 acquisitions — which consume cash and leave less cushion if growth slows.
The 12-month forecast splits into a base case (55% probability) of $1,400–1,500, a bull case (25%) of $1,600–1,700, and a bear case (20%) of $940–1,050. The base case assumes high-20s to low-30s revenue growth, gross margin near 83%, and 2027 EPS tracking the $73.21 consensus, holding the stock around the $1,463.40 average target between the $1,350–1,365 support and the $1,460 52-week high. The bull case requires oral GLP-1 expansion and EPS revisions toward the $78.11 high estimate to justify the $1,700 high target, roughly +18% from current levels. The bear case hinges on Novo's oral Wegovy and CagriSema taking share and compressing the multiple toward 20x, a path to the $940 low target near -35%. The base case is most likely because the analyst consensus of 25 Buy, 4 Hold, and 2 Sell already reflects durable growth without assuming a competitive shock.
LLY is fairly valued at consensus and not stretched relative to its own history, though it carries a clear premium to pharma peers. It trades at 46.58x trailing earnings but only 28.50x forward earnings, a 39% compression that implies the market expects substantial EPS growth toward the $73.21 2027 consensus, and the PEG of 0.48 says growth more than pays for the multiple. Against peers, however, 14.81x PS and 15.39x EV/Sales dwarf the 3–6x typical of large-cap pharma, and 36.37x P/B reflects a growth multiple rather than a value one. Within its own multi-year band (trailing PE ranged from about 27.8x to 205x), the current 46.58x sits in the middle-to-lower portion, meaning the rally has been earnings-driven rather than pure multiple expansion. The market is therefore paying a premium for continued 30%+ growth, not for a turnaround or a discount.
From a risk/reward standpoint LLY is a reasonable but not compelling buy at $1,443.50: the $1,463.40 average analyst target implies only about +1.4% upside, and the stock sits at roughly 98.9% of its 52-week range (low $850.51, high $1,460.00). The quality of the business is not in question — 38.61% YoY revenue growth, 83.04% gross margin, and a PEG of 0.48 — but the post-Q3 re-rating has already captured much of the near-term value. The biggest downside risk is competitive share loss to Novo's oral Wegovy and CagriSema, which the $940 low target prices at roughly -35%. It is a good buy for long-term growth investors willing to accumulate on pullbacks toward the $1,350–1,365 support, and a less attractive chase for short-term traders at all-time highs.
LLY is better suited to long-term holding than short-term trading, though its low beta of 0.389 and shallow -23.31% max drawdown make it less volatile than the absolute price suggests. The growth stage is still expansionary — revenue stepped from $19.799B in Q1 to $22.974B in Q2 to $24.397B in Q3 — and earnings visibility is supported by raised 2026 guidance of up to $92B and 2027 consensus EPS of $73.21, which favors a multi-year compounding horizon. The 0.56% dividend yield and 26.09% payout ratio mean income is incidental, so total return depends on earnings growth and multiple stability rather than distributions. Short-term traders face a stock at 98.9% of its 52-week range with only +1.4% upside to consensus, a poor risk/reward for momentum entries. A suggested minimum holding period is 18–24 months, long enough to capture the oral GLP-1 readouts and 2027 estimate revisions that drive the bull case.

